Vimarsana
Biggest News Aggregation in the World

Page 10 - Philipp Mathieu News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Philipp Mathieu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Philipp Mathieu Today - Breaking & Trending Today

Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d t - Vimarsana News

Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d t

Announced, that the Centers for Medicare & Medicaid Services (CMS) published a preliminary payment...

Immunovia AB: Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d test - Vimarsana News

Immunovia AB: Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d test

LUND, Sweden, Sept. 26, 2022 /PRNewswire/ -- Immunovia AB (NASDAQ Stockholm: IMMNOV) announced, that the Centers for Medicare & Medicaid Services (CMS) published a preliminary payment determination

Immunovia AB: Immunovia Publishes Interim Report Jan-June 2022 - Vimarsana News

Immunovia AB: Immunovia Publishes Interim Report Jan-June 2022

LUND, Sweden, Aug. 24, 2022 /PRNewswire/ -- April-June 2022 Net sales amounted to kSEK 103 (38) divided between sales of tests kSEK 45 and royalties kSEK 58 Net earnings amounted to

Immunovia Publishes Interim Report Jan-June 2022 - Vimarsana News

Immunovia Publishes Interim Report Jan-June 2022

/PRNewswire/ -- April-June 2022 Net sales amounted to kSEK 103 (38) divided between sales of tests kSEK 45 and royalties kSEK 58 Net earnings amounted to MSEK...

Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase - Vimarsana News

Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase

A live and archived webcast will be available on the 'Investors' section of the Immunovia website at...